Skip to main content

Select Drug Profiles

FDA Approvals, In the News

First Chemoimmunotherapy Regimen Granted Accelerated Approval for Patients with Previously Treated DLBCL

ASCO 2019 - Chronic Lymphocytic Leukemia

Effect of Fixed-Duration Venetoclax plus Obinutuzumab on Progression-Free Survival and Minimal Residual Disease Status in Treatment-Naïve Patients with CLL and Comorbidities

ASCO 2019 - Chronic Lymphocytic Leukemia

Three-Year Follow-Up of Acalabrutinib and Obinutuzumab in Treatment-Naïve and Relapsed/Refractory CLL

ASCO 2019 - Chronic Lymphocytic Leukemia

Comparison of 3 Rituximab-Containing Regimens as Primary Therapy in Patients with WM

ASCO 2019 - Chronic Lymphocytic Leukemia

Patient-Reported Outcomes with Ibrutinib-Rituximab in WM: Results from iNNOVATE

ASCO 2019 - Chronic Lymphocytic Leukemia

Evaluation of MRD with Lisocabtagene Maraleucel, a CD19-Directed CAR T Therapy, in Patients with Relapsed/Refractory CLL/SLL

ASCO 2019 - Chronic Lymphocytic Leukemia

Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL

ASCO 2019 - Chronic Lymphocytic Leukemia

Evaluation of the PI3Kδ Inhibitor ME-401 in Patients with Relapsed/Refractory Follicular Lymphoma

ASCO 2019 - Chronic Lymphocytic Leukemia

Smart Start: Final Results of Rituximab, Lenalidomide, and Ibrutinib Lead-In Therapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

ASCO 2019 - Chronic Lymphocytic Leukemia

Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory CLL

Page 51 of 244
Results 501 - 510 of 2434